Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04935359
Title	Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	pancreatic ductal adenocarcinoma
Therapies	Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| SVK \| NOR \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUS